Published:
Fitch Rates DuPont's Senior Unsecured Notes 'A'; Outlook Remains Negative
NEW YORK - (BUSINESS WIRE) - Fitch Ratings has assigned an 'A' rating to E.I. DuPont de Nemours and
Company's (DuPont) issuance of $2 billion senior unsecured notes, split
in a $1 billion 3.25% five-year tranche and a $1 billion 4.625% ten-year
tranche. Net proceeds from the offering will be used to refinance
upcoming debt maturities and for general corporate purposes.
Fitch's current ratings of DuPont are as follows:
--Issuer Default Rating (IDR) 'A';
--Bank credit facility 'A';
--Senior unsecured debt 'A';
--Commercial paper 'F1';
--Short-term IDR 'F1';
The Rating Outlook is Negative.
DuPont's ratings reflect the company's leading market positions, its
integrated operations, its global reach and a well-diversified portfolio
of products and brands. The company's leading competitive position and
the more specialty and innovative nature of the portfolio tends to
provide more stable cash flow than a commodity chemical producer. Albeit
affected by the current recession and still weak economic demand,
DuPont's financial strategy is conservative, which is emphasized by its
low leverage relative to cash flow. Last 12 months (LTM) (to Sept. 30,
2009) funds from operations were in excess of 40% of gross balance sheet
debt and net debt/operating EBITDA was 2.3 times (x). Even prior to the
$2 billion notes issuances, liquidity remained strong at $5.9 billion,
consisting of $2.2 billion cash on hand, $0.9 billion marketable
securities and $2.8 billion availability under committed credit
facilities with multi-year maturities as of Sept. 30, 2009. LTM free
cash flow was approximately $0.5 billion after $1.6 billion capex and
$1.5 billion dividends. Fitch expects LTM free cash flow to remain
positive through the cycle. DuPont repaid $894 million notes in October.
Proceeds from the $2 billion notes issuances cover the company's $0.9
billion maturity of its 4.125% notes in 2010 and most of its
approximately $1.7 billion other short-term debt maturities including
outstanding commercial paper. Medium-term maturities are very manageable
with only $13 million coming due in 2011, $400 million in 2012 and $1.8
billion in 2013.
The Negative Outlook is based on the expectation that demand for
chemical products from cyclical end-user markets such as automotives and
construction will recover only slowly and gradually over the next
several quarters. As a consequence, Fitch expects that DuPont's
operating and financial performance will remain below the company's
historical performance over the next several quarters. The downside risk
is partly mitigated by restructuring initiatives taken by management
which focus on fixed cost, working capital and capital expenditure
reductions. The Negative Outlook also takes into account the anticipated
loss of almost all of the estimated $1 billion in annual pharmaceutical
royalties from the hypertension drug Cozaar/Hyzaar in 2009 after U.S.
patent expiry in April 2010. DuPont projects that these royalties will
decline to $300 million-$350 million next year and to $70 million in
fiscal 2012. In the current economic environment, DuPont will find it
significantly more difficult to replace the royalty stream with growth
and profits from new and existing chemical and agricultural products.
DuPont is the second largest chemical company based on revenues, with
leading market share in a number of specialty segments. Chemicals
operations are highly integrated resulting in cost advantages across the
business cycle. Going forward, DuPont will report its results in seven
reporting segments, Agriculture & Nutrition, Electronics &
Communications, Performance Coatings, Performance Materials, Safety &
Protection, Performance Chemicals, and Pharmaceuticals.
Additional information is available at www.fitchratings.com.
The ratings above have been initiated by Fitch as a service to
investors. The issuer did not participate in the rating process other
than through the medium of its public disclosure.
ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND
DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING
THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS.
IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE
AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE WWW.FITCHRATINGS.COM.
PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS
SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS
OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES
AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF
THIS SITE.
Fitch Ratings, New York
Thomas Dohrmann, +1-212-908-0637
Sean
T. Sexton, CFA, +1-312-368-3130 (Chicago)
Media Relations:
Cindy
Stoller, +1-212-908-0526
cindy.stoller@fitchratings.com
Copyright © 2009, Business Wire, Inc., All rights reserved.
Copyright © 2009, NewsBlaze,
Daily News
Tags: Business wire, new york, Medical, Consulting, Accounting and other Professional Services, Banking and Finance